atezolizumab
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
atezolizumab
Oct 19, 2024, 00:08 |
Blog
Amol Akhade: Lurbinectedin and Atezolizumab show significant benefits in ES-SCLC maintainence
Amol Akhade shared a post on X: "Lurbinectedin plus Atezo shows Both PFS and OS benifit…
Oct 17, 2024, 17:51 |
Blog
Shahrin Ahmed: Liver Cancer Awareness Month
Shahrin Ahmed, Medical Specialist at Canadian Cancer Society, shared a post on X: ''Liver Cancer…
Oct 17, 2024, 12:57 |
Insight
Antonio Calles: Massive news for patients with SCLC
Antonio Calles, Medical Specialist in Medical Oncology at Gregorio Marañón General University Hospital, shared a…
Oct 8, 2024, 10:06 |
Dialogues
ASCO24 Updates: Dr. Laurence Albiges on KIM1: A Promising Biomarker in RCC Treatment
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Oct 5, 2024, 13:04 |
Insight
Highlights from ILCS24 by Stephen V Liu
The 6th International Lung Cancer Summit took place as a hybrid event in Lausanne, Switzerland,…
Sep 25, 2024, 13:30 |
Blog
Matteo Dugo: Neoadjuvant atezolizumab plus chemotherapy in TNBC
Matteo Dugo shared a post on LinkedIn, about recent paper published in Clinical Cancer Research:…
Sep 22, 2024, 12:38 |
Blog
Amol Akhade: Cabozantinib plus Atezolizumab vs second-line NHT in prostate cancer
Amol Akhade shared a post on LinkedIn: ''Cabozantinib plus Atezolizumab versus second-line Non-hormonal Therapy (NHT)…
Sep 21, 2024, 13:02 |
Blog
Final OS data from the phase III CONTACT-02 trial at ESMO24
ESMO (European Society for Medical Oncology) shared a post on LinkedIn: ''Final OS data from…
Sep 17, 2024, 10:36 |
Insight
Elisabetta Bonzano: First-line carboplatin-cyclophosphamid versus paclitaxel for mTNBC
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X: “ First-line carboplatin-cyclophosphamid…
Sep 16, 2024, 15:00 |
Insight
Insights from ESMO24 Day 3
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 10, 2024, 16:09 |
Societies
Highlights from WCLC24 by Stephen V Liu Part 2
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 8, 2024, 14:09 |
Insight
Article of the day, September 8th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Sep 5, 2024, 15:04 |
Insight
Article of the day, September 5th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 16, 2024, 14:13 |
Insight
OS rates for IMpower133 and IMbrella A extension study in SCLC
Biagio Ricciuti shared a paper by Martin Reck et al. on X, adding: “Five-year survival…
Jul 29, 2024, 16:27 |
Insight
Amol Akhade: It is time to take care of "missing third arm of the trial" syndrome
Amol Akhade shared his remarks on a study by Helen J Ross et al on…
Jul 24, 2024, 00:59 |
Insight
Luca Licata: The fate of immunotherapy trials in breast cancer
Marco Mariani, Resident in Medical Oncology at San Raffaele Scientific Institute, shared a post on X…
Jul 12, 2024, 14:31 |
Blog
Sumanta K. Pal: Subanalysis of patients in IMmotion010 with sarcomatoid features
Sumanta K. Pal, Kidney Cancer Professor at City of Hope shared an article by Jose…
Jul 8, 2024, 04:52 |
Insight
Spotlight on Alveolar soft part sarcoma - NCI
National Cancer Institute (NCI) shared a post on LinkedIn: "Alveolar soft part sarcoma (ASPS) is…
Jul 6, 2024, 05:13 |
Insight
Tanja Obradovic: Choosing immunotherapy treatment for early resectable NSCLC
Tanja Obradovic shared on LinkedIn: "Choosing immunotherapy treatment options with PD(L)-1 inhibitors for early resectable non–small…
Jun 29, 2024, 03:18 |
Blog
Peter Schmid's findings on atezolizumab and sacituzumab govitecan for advanced TNBC - ESMO
ESMO shared a post on LinkedIn: “For ESMO members: Breaking Science in Breast Cancer. Peter Schmid…
Jun 28, 2024, 11:47 |
Societies
Anwaar Saeed: Thrilled to present mature data from phase 2 CRC expansion cohort
Anwaar Saeed, Associate Professor and Chief of Gastrointestinal Medical Oncology at University of Pittsburgh, shared…
Jun 27, 2024, 02:53 |
Blog
Tanja Obradovic: Tempest Therapeutics just announced very good results from ongoing global clinical study with Amezalpat
Tanja Obradovic shared on LinkedIn: . “Are we to expect completely new mechanism of action…
Jun 16, 2024, 20:00 |
Insight
Daneng Li: SKYSCRAPER-14 a Phase III study on advanced hepatocellular carcinoma
Daneng Li, GI Medical Oncologist at City of Hope, shared on X/Twitter: "Out now, the…
Jun 10, 2024, 02:15 |
Insight
Final results from the SAUL study are in - International Urology Cancer Summit
International Urology Cancer Summit shared a post on LinkedIn: “Final results from the SAUL study…
May 27, 2024, 07:37 |
Blog
Eric K. Singhi on BEAT-SC: Phase 3 Bev + Chemo/Atezo v Chemo/Atezo in 1L ES-SCLC
Eric K. Singhi shared the following on X: “BEAT-SC: Phase 3 Bev + Chemo/Atezo v Chemo/Atezo…
May 23, 2024, 06:36 |
Insight
María Natalia Gandur Quiroga: New insights on immunotherapy rechallenge in mRCC
María Natalia Gandur Quiroga shared on X: "New insights on immunotherapy rechallenge in mRCC! Key…
May 22, 2024, 01:03 |
Insight
Nicholas Hornstein: The first trial to demonstrate benefit of systemic therapy in appendiceal cancer
Nicholas Hornstein, Oncology Fellow at MD Anderson Cancer Centre, shared a post by Cancer Research…
May 18, 2024, 01:12 |
Opinion
Results from the IMpassion132 trial presented at ESMO Breast 24
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “Results from the IMpassion132 trial presented…
May 16, 2024, 16:51 |
Insight
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
In the fast-growing field of oncology, we are witnessing significant advances in several treatment modalities…
May 13, 2024, 14:29 |
Insight
Jarushka Naidoo: A step forward in implementing anti-PD(L)1 across growing not otherwise specified of indications?
Jarushka Naidoo shared on X: "Ph III IMscin001 trial of Subcutaneous (sc) vs IV Atezolizumab…
May 12, 2024, 13:31 |
Blog
Stephen Liu: Update from phase 3 IMscin001 trial JTO and JTO CRR
Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter: “Update from…
Mar 18, 2024, 19:11 |
Blog
Fredrick Chite Asirwa: International Cancer Institute clinic is recruiting breast cancer patients for clinical trials currently
Fredrick Chite Asirwa, CEO/Executive Director of International Cancer Institute, posted on LinkedIn: "To contribute to…
Mar 4, 2024, 17:07 |
Drugs
George Mellgard: We delve into the complexities of FDA Accelerated Approvals in oncology using lessons from 16 withdrawn accelerated approvals in the past decade
George Mellgard, Medical Student at Columbia University Irving Medical Center in NYC, shared on X/Twitter:…
Jan 30, 2024, 19:29 |
Blog
Vrouyr Bilemjian: We have developed a tumor targeting drug delivery systems
Vrouyr Bilemjian, Solutions and Strategy Consultant at Innoplexus, made the following post on LinkedIn: "Excited…
Jan 16, 2024, 05:48 |
Drugs
Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
Dec 12, 2023, 17:44 |
Insight
Piotr Wysocki: SABCS2023 - Adjuvant chemoimmunotherapy does not benefit TNBC patients
Piotr Wysocki, Head of Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn: "SABCS2023…
Nov 21, 2023, 02:13 |
Blog
Salah-Eddin Al-Batran: Our group is happy to announce the publication of the IKF-633/DANTE trial (phase 2 portion) in Journal of Clinical Oncology
Salah-Eddin Al-Batran, Director of IKF-The Frankfurt Institute of Clinical Cancer Research, shared on LinkedIn: "Dear…
Sep 19, 2023, 20:03 |
Drugs
Gabriela Kramer-Marek: I have just presented the very first results of our recently initiated clinical study evaluating 89Zr-DFO-Atezolizumab in patients with newly diagnosed glioblastoma!
Aug 22, 2023, 09:55 |
Drugs
Neeraj Agarwal: Breaking news: Glad to report the news from ph3 Contact-2 trial Cabozantinib + atezolizumab significantly improved outcomes in mCRPC prostate cancer.
Neeraj Agarwal stated on Twitter: "Breaking news: Glad to report the news from ph3 Contact-2 trial…
Aug 9, 2023, 21:00 |
Drugs
Atezolizumab/bevacizumab for the management of HCC in 1st setting - Arndt Vogel
🔥 off the press: Atezolizumab/bevacizumab for the management of HCC in 1st setting: systematic literature…
Jul 27, 2023, 06:55 |
Blog
A durable antitumor activity to atezolizumab was observed in a subset of penile cancer - Gustavo
Although failed to achieve, a durable antitumor activity to atezolizumab was observed in a subset…
All:
41
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube